Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Ahead: Ten Potential Medtech Takeover Targets

This article was originally published in The Gray Sheet

Executive Summary

Device firms have already been active with M&A deals in 2014. Here are 10 companies to look for as potential acquisition targets going forward.

Advertisement

Related Content

Editors' Picks: Six Themes From 2014
Philips Increases Bet On Imaged-Guided Therapy With Volcano Buy
Wright Moves More To Extremes With Tornier Purchase Agreement
Danaher Will Top Dental Market With $2.2 Billion Nobel Biocare Buy
Boston Sci Links With Guidewire Specialist In Pursuit Of 2015 FFR Launch
Ankles Away: Stryker Raises Bet On Extremities With SBi Acquisition
Volcano Cuts Deeper Into Peripheral Market With AtheroMed Buy
New Ortho Juggernaut: Zimmer Acquires Biomet For $13.35 Billion
Wright, MicroPort Deal Signals Shifts In Global Ortho Industry
Siemens Claims Top IVD Slot With $7 Billion Dade Behring Purchase

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT033277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel